BC Innovations | Jun 18, 2015
Distillery Techniques

Techniques: Hybrid poly(D,L-lactide-co-glycolide) (PLGA) polymer/lipid nanoparticles for siRNA delivery

Drug delivery TECHNOLOGY: Nanoparticles A hybrid cationic lipid-polymer nanoparticle could enable safe, long-acting delivery of siRNA to tumors. The hybrid nanoparticles consisted of a PLGA polymer/lipid core that readily assembled into a complex with its...
BC Extra | May 1, 2013
Financial News

Arrowhead to raise $36M in private placement

Arrowhead Research Corp. (NASDAQ:ARWR) plans to raise $36 million through the sale of 14.3 million shares at $1.83 and 9,900 series B convertible preferred shares at $1,000 in a private placement. Each series B share...
BC Week In Review | Jul 16, 2012
Clinical News

Adipotide: Phase I started

Arrowhead said the University of Texas MD Anderson Cancer Center began an open-label, U.S. Phase I trial to evaluate 5 dose levels of Adipotide daily for 28 days in about 39 patients with castration-resistant prostate...
BC Week In Review | Jul 9, 2012
Clinical News

Arrowhead preclinical data

In a mouse model of obesity, adipotide significantly improved insulin sensitivity, improved glucose tolerance and reduced serum triglycerides. Data were published in the Journal of the American Diabetes Association. Adipotide is a peptidomimetic consisting of...
BioCentury | Jul 9, 2012
Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
BC Innovations | Nov 17, 2011
Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Prohibitin 1 (PHB; PHB1) Nonhuman primate studies suggest a PHB1-binding peptidomimetic called adipotide could help treat obesity. In obese...
BC Innovations | Nov 17, 2011
Strategy

MD Anderson's private screening

Less than two years after The University of Texas MD Anderson Cancer Center carved up the IP for its in vivo phage display screening platform, the two biotech licensees have preclinical proof-of-concept data and preliminary...
BC Week In Review | Apr 11, 2011
Company News

Arrowhead endocrine news

Arrowhead increased its stake in its Ablaris Therapeutics Inc. subsidiary to 64% from 55% after investing an additional $800,000 in the subsidiary in the second and final closing of a series A round. Ablaris raised...
BC Week In Review | Jan 3, 2011
Company News

Arrowhead, M.D. Anderson Cancer Center deal

The center granted Arrowhead an exclusive, worldwide license to technology related targeting the prohibitin 1 (PHB1) to treat weight-loss and obesity-related metabolic conditions. Arrowhead launched a new subsidiary, Ablaris Therapeutics Inc. , to commercialize the technology,...
BC Innovations | Feb 4, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Prohibitin 1 (PHB1) In vitro and mouse studies suggest that inhibiting PHB1 could help treat paclitaxel-resistant cancers. Proteomics analysis showed that PHB1 was overexpressed...
Items per page:
1 - 10 of 14